Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Liver Diseases

Free Subscription Articles published in J Gastroenterol Retrieve available abstracts of 37 articles: HTML format Text format

Single Articles

October 2018
1. IIO E, Matsuura K, Shimada N, Atsukawa M, et al
   TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy.
   J Gastroenterol. 2018 Oct 31. pii: 10.1007/s00535-018-1526.
   PubMed     Text format     Abstract available
   
   
   
2. PARK HE, Lee H, Choi SY, Kwak MS, et al
   Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter.
   J Gastroenterol. 2018 Oct 4. pii: 10.1007/s00535-018-1516.
   PubMed     Text format     Abstract available
   
   
   September 2018
3. TAKEHARA T, Sakamoto N, Nishiguchi S, Ikeda F, et al
   Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
   J Gastroenterol. 2018 Sep 10. pii: 10.1007/s00535-018-1503.
   PubMed     Text format     Abstract available
   
   
   July 2018
4. SHIMA T, Uto H, Ueki K, Kohgo Y, et al
   Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients.
   J Gastroenterol. 2018 Jul 13. pii: 10.1007/s00535-018-1494.
   PubMed     Text format     Abstract available
   
   
   May 2018
5. ENOOKU K, Kondo M, Fujiwara N, Sasako T, et al
   Hepatic IRS1 and ss-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients.
   J Gastroenterol. 2018 May 10. pii: 10.1007/s00535-018-1472.
   PubMed     Text format     Abstract available
   
   
   
6. ORIMO T, Kamiyama T, Mitsuhashi T, Kamachi H, et al
   Impact of tumor localization on the outcomes of surgery for an intrahepatic cholangiocarcinoma.
   J Gastroenterol. 2018 May 2. pii: 10.1007/s00535-018-1469.
   PubMed     Text format     Abstract available
   
   
   April 2018
7. KAKISAKA K, Suzuki Y, Fujiwara Y, Abe T, et al
   Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease.
   J Gastroenterol. 2018 Apr 21. pii: 10.1007/s00535-018-1468.
   PubMed     Text format     Abstract available
   
   
   December 2017
8. SHINKAI N, Nojima M, Iio E, Matsunami K, et al
   High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
   J Gastroenterol. 2017 Dec 29. pii: 10.1007/s00535-017-1424.
   PubMed     Text format     Abstract available
   
   
   November 2017
9. SUZUKI Y, Mori T, Yokoyama M, Kim S, et al
   A proposed severity classification system for hepatolithiasis based on an analysis of prognostic factors in a Japanese patient cohort.
   J Gastroenterol. 2017 Nov 8. doi: 10.1007/s00535-017-1410.
   PubMed     Text format     Abstract available
   
   
   
10. SHANG L, Hosseini M, Liu X, Kisseleva T, et al
    Human hepatic stellate cell isolation and characterization.
    J Gastroenterol. 2017 Nov 1. doi: 10.1007/s00535-017-1404.
    PubMed     Text format     Abstract available
    
    
    October 2017
11. KOYAMA N, Yamazaki T, Kanetsuki Y, Hirota J, et al
    Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma.
    J Gastroenterol. 2017 Oct 30. doi: 10.1007/s00535-017-1398.
    PubMed     Text format     Abstract available
    
    
    
12. NAKAO M, Nakayama N, Uchida Y, Tomiya T, et al
    Nationwide survey for acute liver failure and late-onset hepatic failure in Japan.
    J Gastroenterol. 2017 Oct 13. doi: 10.1007/s00535-017-1394.
    PubMed     Text format     Abstract available
    
    
    
13. WANG W, Pan Q, Fuhler GM, Smits R, et al
    Erratum to: Action and function of Wnt/beta-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma.
    J Gastroenterol. 2017 Oct 11. doi: 10.1007/s00535-017-1392.
    PubMed     Text format     Abstract available
    
    
    September 2017
14. CHAYAMA K, Suzuki F, Karino Y, Kawakami Y, et al
    Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
    J Gastroenterol. 2017 Sep 25. doi: 10.1007/s00535-017-1391.
    PubMed     Text format     Abstract available
    
    
    
15. IMPERATORE N, Tortora R, Testa A, Gerbino N, et al
    Erratum to: Proton pump inhibitors as risk factor for metabolic syndrome and hepatic steatosis in coeliac disease patients on gluten-free diet.
    J Gastroenterol. 2017 Sep 19. doi: 10.1007/s00535-017-1393.
    PubMed     Text format     Abstract available
    
    
    August 2017
16. KAWAGUCHI K, Honda M, Ohta H, Terashima T, et al
    Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.
    J Gastroenterol. 2017 Aug 28. doi: 10.1007/s00535-017-1386.
    PubMed     Text format     Abstract available
    
    
    
17. IMPERATORE N, Tortora R, Anna T, Gerbino N, et al
    Proton pump inhibitors as risk factor for metabolic syndrome and hepatic steatosis in coeliac disease patients on gluten-free diet.
    J Gastroenterol. 2017 Aug 19. doi: 10.1007/s00535-017-1381.
    PubMed     Text format     Abstract available
    
    
    
18. KOBAYASHI K, Maruyama H, Kiyono S, Ogasawara S, et al
    Application of transcutaneous ultrasonography for the diagnosis of muscle mass loss in patients with liver cirrhosis.
    J Gastroenterol. 2017 Aug 18. doi: 10.1007/s00535-017-1378.
    PubMed     Text format     Abstract available
    
    
    
19. SHIDA T, Akiyama K, Oh S, Sawai A, et al
    Skeletal muscle mass to visceral fat area ratio is an important determinant affecting hepatic conditions of non-alcoholic fatty liver disease.
    J Gastroenterol. 2017 Aug 8. doi: 10.1007/s00535-017-1377.
    PubMed     Text format     Abstract available
    
    
    
20. IKEDA M, Kudo M, Aikata H, Nagamatsu H, et al
    Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.
    J Gastroenterol. 2017 Aug 1. doi: 10.1007/s00535-017-1374.
    PubMed     Text format     Abstract available
    
    
    July 2017
21. KITAJIMA Y, Takahashi H, Akiyama T, Murayama K, et al
    Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis.
    J Gastroenterol. 2017 Jul 24. doi: 10.1007/s00535-017-1370.
    PubMed     Text format     Abstract available
    
    
    
22. SEKO Y, Sumida Y, Sasaki K, Itoh Y, et al
    Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.
    J Gastroenterol. 2017 Jul 1. doi: 10.1007/s00535-017-1364.
    PubMed     Text format     Abstract available
    
    
    June 2017
23. HIRAMINE Y, Uojima H, Nakanishi H, Hiramatsu A, et al
    Response criteria of tolvaptan for the treatment of hepatic edema.
    J Gastroenterol. 2017 Jun 29. doi: 10.1007/s00535-017-1366.
    PubMed     Text format     Abstract available
    
    
    
24. OKANOUE T, Ebise H, Kai T, Mizuno M, et al
    A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis.
    J Gastroenterol. 2017 Jun 6. doi: 10.1007/s00535-017-1355.
    PubMed     Text format     Abstract available
    
    
    
25. TAJIRI K, Kawai K, Sugiyama T
    Strain elastography for assessment of liver fibrosis and prognosis in patients with chronic liver diseases.
    J Gastroenterol. 2017;52:724-733.
    PubMed     Text format     Abstract available
    
    
    May 2017
26. MASUDA K, Ono A, Aikata H, Kawaoka T, et al
    Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
    J Gastroenterol. 2017 May 29. doi: 10.1007/s00535-017-1352.
    PubMed     Text format    
    
    
    
27. MASUDA K, Ono A, Aikata H, Kawaoka T, et al
    Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
    J Gastroenterol. 2017 May 4. doi: 10.1007/s00535-017-1348.
    PubMed     Text format     Abstract available
    
    
    April 2017
28. KIM TJ, Sinn DH, Min YW, Son HJ, et al
    A cohort study on Helicobacter pylori infection associated with nonalcoholic fatty liver disease.
    J Gastroenterol. 2017 Apr 5. doi: 10.1007/s00535-017-1337.
    PubMed     Text format     Abstract available
    
    
    
29. FLOREANI A, Tanaka A, Bowlus C, Gershwin ME, et al
    Geoepidemiology and changing mortality in primary biliary cholangitis.
    J Gastroenterol. 2017 Apr 1. doi: 10.1007/s00535-017-1333.
    PubMed     Text format     Abstract available
    
    
    March 2017
30. CAI X, Hayashi S, Fang C, Hao S, et al
    Pu'erh tea extract-mediated protection against hepatosteatosis and insulin resistance in mice with diet-induced obesity is associated with the induction of de novo lipogenesis in visceral adipose tissue.
    J Gastroenterol. 2017 Mar 31. doi: 10.1007/s00535-017-1332.
    PubMed     Text format     Abstract available
    
    
    
31. ZHANG AY, Lai CL, Huang FY, Seto WK, et al
    Deep sequencing analysis of quasispecies in the HBV pre-S region and its association with hepatocellular carcinoma.
    J Gastroenterol. 2017 Mar 28. doi: 10.1007/s00535-017-1334.
    PubMed     Text format     Abstract available
    
    
    
32. KISHIDA Y, Okubo H, Ohno H, Oki K, et al
    Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model.
    J Gastroenterol. 2017 Mar 27. doi: 10.1007/s00535-017-1331.
    PubMed     Text format     Abstract available
    
    
    
33. HASEBE T, Tanaka H, Sawada K, Nakajima S, et al
    Bone morphogenetic protein-binding endothelial regulator of liver sinusoidal endothelial cells induces iron overload in a fatty liver mouse model.
    J Gastroenterol. 2017;52:341-351.
    PubMed     Text format     Abstract available
    
    
    February 2017
34. SETO WK, Yuen MF
    Nonalcoholic fatty liver disease in Asia: emerging perspectives.
    J Gastroenterol. 2017;52:164-174.
    PubMed     Text format     Abstract available
    
    
    
35. MORIO R, Hyogo H, Hatooka M, Morio K, et al
    The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease.
    J Gastroenterol. 2017;52:253-262.
    PubMed     Text format     Abstract available
    
    
    
36. MIYAKE T, Hirooka M, Yoshida O, Furukawa S, et al
    Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels.
    J Gastroenterol. 2017;52:237-244.
    PubMed     Text format     Abstract available
    
    
    June 2016
37. YAMADA N, Sanada Y, Tashiro M, Hirata Y, et al
    Serum Mac-2 binding protein glycosylation isomer predicts grade F4 liver fibrosis in patients with biliary atresia.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: